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Abstract Purpose We evaluated the safety, tolerability, and
pharmacokinetics (PK) of EMD 525797 (DI17E6), a hu-
manized monoclonal antibody targeting αv-integrins, in
healthy subjects. Methods In this first-in-human, double-
blind, placebo-controlled, randomized Phase 1 study,
healthy male volunteers were consecutively assigned to 6
ascending single-dose cohorts of 35, 100, 250, 500, 1000,
or 1500 mg. Per dose cohort, EMD 525797 or placebo was
administered over 1 h as an intravenous 250-mL infusion to
6 and 3 volunteers, respectively. Escalation to the next dose
level was based on evaluation of safety, tolerability, and PK
data. Results Fifty-five subjects (aged 18–45 years) were
randomized. Twenty-seven of 37 (73 %) subjects receiv-
ing EMD 525797 reported a total of 61 adverse events
(AEs), including 38 events (in 17 subjects) considered by
the investigator to be treatment related. A total of 35
AEs were reported by 14 of 18 (78 %) placebo-treated
subjects. The most commonly occurring AEs were gas-
trointestinal disorders, abnormal laboratory values, and
increased or decreased biochemistry and/or hematology
values, as well as headaches, which occurred at a slightly
higher frequency in the EMD 525797 group compared
with placebo. There were no serious AEs or deaths.
EMD 525797 PK appeared to be dose dependent, especially
at lower doses. Conclusion Ascending single doses of EMD
525797 were shown to be safe and well tolerated. No safety
concerns were identified. This study supports the ongoing
investigation of EMD 525797.
Keywords αv integrins overexpression . EMD 525797
(DI17E6)
Introduction
Integrins are a large family of heterodimeric transmem-
brane glycoproteins consisting of an alpha (α) and a beta
(ß) subunit. They mediate a wide range of cell-to-
extracellular matrix (ECM) and cell-to-cell adhesive inter-
actions that occur as part of normal tissue function and in
diverse human pathologies [1]. Integrins have been shown
to play a role in cellular proliferation and the regulation of
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cell-cycle progression [2], cellular invasion and migration
[3, 4], cell signaling [3, 4], and as regulators of gene
transcription [5]. In cancer, integrins have demonstrated a
direct role in tumor progression via their effects on tumor cell
survival, angiogenesis, and metastasis [6, 7]. As a result,
agents that specifically target integrin function have potential
as anticancer therapies. Thus far, many therapeutics targeting
integrins are in clinical development in and outside of oncol-
ogy, including 5 that have been approved for clinical use in
areas such as multiple sclerosis or thrombosis [1].
The αv-integrins are a subfamily of integrins composed of
5 members whose functions include regulation of cell adhe-
sion to ECM, and cellular proliferation and migration [5, 6].
These αv-integrins are highly expressed on tumor cells and
the tumor vasculature of many human cancers [8–10]. Be-
cause of the nature and pathologic functions of integrins, a
lasting integrin inhibition would be desirable. Therefore, an-
tibodies like EMD 525797 were designed to inhibit cell-cell
interactions mediated by one or more of these integrins [11].
EMD 525797 (DI17E6) is a novel, humanized monoclo-
nal IgG2 antibody specifically directed against the αv-
subunit of human integrin receptors [1]. This antibody
inhibits ligand binding to all αv heterodimers (αvß1,
αvß3, αvß5, αvß6, αvß8) without cross-reacting with oth-
er members of the integrin family. The binding of EMD
525797 to the αv heterodimers antagonizes their interaction
with cognate ligands in the ECM [1], preventing cell at-
tachment and motility, which can trigger apoptosis. As
preclinical data have shown that EMD 525797 targets tu-
mor cells and the microenvironment including angiogenic
blood vessels, and inhibits tumor growth in mouse xeno-
graft human tumor models (unpublished data), further clin-
ical development was warranted. Results from a Phase 1
trial in patients with progressive castration-resistant pros-
tate cancer with bone metastases after chemotherapy
showed EMD 525797 to be well tolerated with potential
antitumor activity [12].
Herein, the results of the first-in-human, Phase 1, ran-
domized, double-blind, placebo-controlled study of EMD
525797 in healthy volunteers are reported, evaluating the
safety, tolerability, and pharmacokinetics (PK) of single




Eligible subjects were healthy male volunteers aged 18 to
45 years who had given their written informed consent. They
were required to be Caucasian with a weight of 55 to 105 kg
and a body mass index of 19 to 29.9 kg/m2. The subjects had
to be healthy, particularly with respect to physical examina-
tion, lung function, vital signs, 12-lead electrocardiogram
(ECG), and laboratory tests (such as hematologic, biochemis-
try, coagulation, and urine analyses). Main exclusion criteria
were evidence of clinically relevant pathology, particularly
severe hepatic or renal impairment, presence of any immuno-
logic disease, history of moderate or severe hypertension,
hypotension, or bleeding disorders, history of neurologic dis-
orders and/or epilepsy; history of hypersensitivity to immune
globulin preparations; regular smoking consumption of more
than 5 cigarettes or equivalent per day; consumption of large
quantities of methylxanthine-containing beverages and inabil-
ity to abstain from caffeine consumption during study partic-
ipation; history of thromboembolic events; and major surgery
within 6 months of screening.
Study design
Healthy volunteers were consecutively assigned to 6 ascend-
ing single-dose cohorts of 35, 100, 250, 500, 1000, and
1500 mg EMD 525797. EMD 525797 or placebo was admin-
istered over 1 h as an intravenous 250-mL infusion without
premedication. Within each dose group, 6 volunteers were
randomized to receive EMD 525797 and 3 to receive placebo.
The study drug was sequentially administered to subgroups of
2 then 3 then 4 subjects (including a single subject receiving
placebo in each subgroup), with the decision to expose more
subjects within each cohort to study drug based on assessment
of safety and tolerability findings at the end of a 2-day obser-
vation period. Escalation to the next dose level was based on
evaluation of safety, tolerability, and PK data. Subjects were
followed for up to 42 days.
Study objectives
The primary objectives were to assess the safety, tolerability,
and PK profile of EMD 525797 administered as one single
dose in healthy male volunteers at various dose levels. The
secondary objective was to evaluate the influence of EMD
525797 on pharmacodynamic parameters.
Study assessments
Safety and tolerability measures included the assessment of
adverse events (AEs), vital signs, physical examination, and
(safety) laboratory parameters. Blood samples were obtain-
ed for assessment of serum concentrations of EMD 525797
using a validated ELISA method with a quantification
range of 233 to 10,000 ng/mL. PK parameters were calcu-
lated according to standard noncompartmental methods
using KINETICA™ software, version 4.4.1. The presence
of anti-EMD 525797 antibodies was investigated using a
validated semi-quantitative two-stage format ELISA assay.
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In addition, we investigated the influence of EMD 525797
on pharmacodynamic parameters and safety biomarkers
such as platelet activation, complement activity, endoge-
nous thrombin potential (ETP), D-dimer, circulating endo-
thelial cells, and circulating endothelial progenitor cells.
The study drug was administered at an in-house facility,
with subjects receiving supervision until 72 h after the start
of infusion. Two additional in-house stays were from day 7
to 8 and day 41 to 42 to guarantee appropriate 24-hour urine
collection for determination of the glomular filtration rate
and α1-microglobulin, and an ophthalmologic examination
on day 41.
Statistical analysis
Study results were analyzed using descriptive statistics. The
safety population included all randomized subjects who had
taken study drug. The PK population included all subjects
randomized to receive EMD 525797 and who provided suffi-
cient data for PK assessment of EMD 525797. AEs were listed
per dose level and analyzed by intensity and relationship to the
study drug. All other variables were analyzed descriptively
per dose level. Dose proportionality for PK parameters was
examined using the power model and by graphic means. No
formal statistics comparisons were planned.
Table 1 Baseline demographics of the healthy volunteers
EMD 525797 Placebo (Pooled) N= 18
35 mg 100 mg 250 mg 500 mg 1000 mg 1500 mg Overall
N= 6 N= 6 N= 6 N= 6 N= 6 N= 7 N= 37
Age, years
Mean (SD) 33.7 (7.3) 37.5 (7.2) 29.3 (7.9) 32.0 (9.3) 36.7 (6.8) 31.4 (7.3) 33.4 (7.7) 31.2 (7.6)
Range 26–42 26–45 18–38 19–43 27–44 24–41 18–45 19–45
Weight, kg
Mean (SD) 90.9 (6.5) 81.9 (9.2) 78.0 (6.0) 67.9 (4.9) 76.1 (7.0) 76.6 (7.9) 78.5 (9.5) 79.7 (9.5)
Range 81.8–97.3 72.7–98.4 69.9–85.1 63.2–76.4 68.4–88.6 67.4–92.2 63.2–98.4 65.3–97.5
Height, cm
Mean (SD) 184 (8.1) 183 (4.8) 180 (6.1) 177 (7.5) 178 (4.5) 182 (5.4) 181 (6.3) 181 (6.4)
Range 171–195 178–191 168–184 167–188 171–183 174–189 167–195 171–196
BMI, kg/m2
Mean (SD) 27.0 (1.7) 24.4 (2.7) 24.0 (1.4) 21.7 (1.2) 24.1 (1.6) 23.2 (2.8) 24.0 (2.5) 24.3 (2.4)
Range 25.0–29.5 22.2–29.7 21.8–25.5 19.9–23.1 22.1–26.5 21.2–29.4 19.9–29.7 19.9–28.2
BMI body mass index; SD standard deviation
Table 2 Overview of reported AEsa, relationship to drug and intensity
EMD 525797 Placebo (Pooled) N= 18
35 mg 100 mg 250 mg 500 mg 1000 mg 1500 mg Overall
N= 6 N= 6 N= 6 N= 6 N= 6 N= 7 N= 37
n (%) E n (%) E n (%) E n (%) E n (%) E n (%) E n (%) E n (%) E
Any AE 4 (67) 6 4 (67) 6 3 (50) 5 6 (100) 18 5 (83) 17 5 (71) 9 27 (73) 61 14 (78) 35
Relationship to drug
Likely 3 (50) 5 3 (50) 3 1 (17) 2 4 (67) 13 4 (67) 12 2 (29) 3 17 (46) 38 12 (67) 21
Not likely 1 (17) 1 3 (50) 3 3 (50) 3 5 (83) 5 3 (50) 5 4 (57) 6 19 (51) 23 8 (44) 14
Intensity
Mild 1 (17) 1 3 (50) 3 2 (33) 2 5 (83) 6 4 (67) 6 3 (43) 4 18 (49) 22 9 (50) 15
Moderate 4 (67) 4b 3 (50) 3 1 (17) 3 4 (67) 11 4 (67) 11 4 (57) 5 20 (54) 37 13 (72) 19
Severe - - - - - - 1 (17) 1 - - - - 1 (3) 1 - -
a Subjects could report more than 1 AE
bOf 2 observed AEs “creatinine renal clearance decreased,” only 1 was counted
AE, adverse event; E, number of events; N/n, number of subjects reporting AEs
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Table 3 Overview of subjects reporting TEAEs according to MedDRA System Organ Class and Preferred Term
EMD 525797 Placebo (Pooled) N= 18
35 mg 100 mg 250 mg 500 mg 1000 mg 1500 mg Overall
N= 6 N= 6 N= 6 N= 6 N= 6 N= 7 N= 37
n (%) E n (%) E n (%) E n (%) E n (%) E n (%) E n (%) E n (%) E
Eye disorders
Eye irritation - - - - - - - - - - - - - - 1 (6) 1
Gastrointestinal disorders
Abdominal pain - - - - - - 1 (17) 1 - - - - 1 (3) 1 - -
Abdominal pain (upper) - - - - - - 1 (17) 1 - - - - 1 (3) 1 - -
Diarrhea - - - - - - - - - - - - - - 1 (6) 1
Flatulence - - - - - - - - 1 (17) 1 - - 1 (3) 1 - -
Nausea - - - - - - - - - - - - - - 1 (6) 2
Toothache - - - - - - 1 (17) 1 - - - - 1 (3) 1 - -
Vomiting - - - - - - 1 (17) 1 - - - - 1 (3) 1 - -
General disorders and administration site conditions
Asthenia - - - - - - - - - - - - - - 1 (6) 1
Chest discomfort - - - - - - - - - - - - - - 1 (6) 1
Chills - - - - - - 1 (17) 1 1 (17) 1 - - 2 (5) 2 - -
Infusion site erythema - - 1 (17) 1 - - - - - - - - 1 (3) 1 - -
Infusion site pain - - - - - - - - - - 1 (14) 1 1 (3) 1 1 (6) 1
Infusion site swelling - - - - 1 (17) 1 - - - - - - 1 (3) 1 - -
Infections and infestations
Nasopharyngitis - - 1 (17) 1 - - 1 (17) 1 1 (17) 1 4 (57) 4 7 (19) 7 5 (28) 5
Rhinitis - - - - - - 1 (17) 1 1 (17) 1 - - 2 (5) 2 - -
Investigations
Blood creatine phosphokinase increased - - - - - - - - 1 (17) 1 - - 1 (3) 1 1 (6) 1
Blood glucose decreased - - - - - - - - 1 (17) 1 - - 1 (3) 1 - -
Blood magnesium increased - - - - - - - - 1 (17) 1 - - 1 (3) 1 - -
Blood triglycerides increased - - - - - - - - 1 (17) 1 - - 1 (3) 1 - -
Body temperature increased - - - - - - 1 (17) 1 1 (17) 1 - - 2 (5) 2 - -
C-reactive protein increased - - - - - - 1 (17) 1 1 (17) 1 - - 2 (5) 2 1 (6) 1
Complement factor decreased - - - - - - - - - - 1 (14) 1 1 (3) 1 - -
Creatinine renal clearance decreased 1 (17) 2 - - 1 (17) 1 - - - - 1 (14) 1 3 (8) 4 3 (17) 3
Glutamate dehydrogenase increased - - - - - - - - - - - - - - 1 (6) 1
High-density lipoprotein decreased - - - - - - - - 1 (17) 1 - - 1 (3) 1 - -
Interleukin 8 level increased 2 (33) 2 3 (50) 3 1 (17) 1 1 (17) 1 - - - - 7 (19) 7 6 (33) 6
Lymphocyte count decreased - - - - - - 1 (17) 1 - - - - 1 (3) 1 - -
Neutrophil count increased - - - - - - - - - - - - - - 1 (6) 1
White blood cell count increased - - - - - - - - - - - - - - 1 (6) 1
TNFα increased - - - - - - - - - - - - - - 1 (6) 1
Metabolism and nutrition disorders
Appetite decreased 1 (17) 1 - - - - - - 1 (17) 1 - - 2 (5) 2 - -
Musculoskeletal and connective tissue disorders
Back pain - - - - - - 1 (17) 1 1 (17) 1 - - 2 (5) 2 - -
Pain in extremity - - - - - - - - 1 (17) 1 - - 1 (3) 1 1 (6) 1
Nervous system disorders
Headache 1 (17) 1 1 (17) 1 - - 4 (67) 4 1 (17) 1 - - 7 (19) 7 2 (11) 2
Hypoaesthesia - - - - 1 (17) 1 - - - - - - 1 (3) 1 - -
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Results
Baseline characteristics and subject disposition
A total of 55 healthymale subjects ranging from 18 to 45 years
of age were randomized, with 37 subjects receiving infusions
of EMD 525797 and 18 subjects receiving placebo. A single
subject assigned to receive EMD 525797 at the 1500-mg dose
level withdrew for personal reasons. Therefore, 54 subjects
completed the study according to protocol. Across all EMD
525797 dose groups and compared with placebo, demograph-
ic characteristics were similar (Table 1).
Safety
Twenty-seven of 37 (73 %) subjects randomized to EMD
525797 reported a total of 61 AEs and 14 of 18 (78 %)
subjects randomized to placebo reported a total of 35 AEs
(Table 2). Thirty-eight AEs reported by 17 (46 %) subjects
who received EMD 525797 and 21 AEs by 12 subjects (67 %)
with placebo were considered by the investigator to be likely
related to study drug. All but one of the AEs reported were
considered by the investigator to be of mild or moderate
intensity (Table 2); only an increased C-reactive protein
(CRP) value observed in a subject in the EMD 525797 500-
mg dose group was assessed as severe. This subject was
additionally suffering from back pain, headache, increased
body temperature with sweating and shivering, stomach
cramps, and vomiting within 24 h and 6 days after EMD
525797 dosing, all AEs of moderate intensity. No serious
AEs occurred and no subject died. Across all dose groups,
the majority of AEs occurred within 48 h of dosing and all
were resolved at the end of the study. In general, AEs occurred
at a similar incidence in the overall EMD 525797 group and
the placebo group. The most commonly occurring
treatment-emergent AEs according to system organ class
were abnormal laboratory values (investigations), gastroin-
testinal disorders, infections and infestations, nervous sys-
tem disorders, and general disorders and administration site
conditions (Table 3).
Overall, treatment with EMD 525797 in ascending doses
from 35 to 1500 mg was safe and well tolerated. Although the
majority of AEs occurred in the 500-mg (n= 18, 30 %) and
1000-mg (n= 17, 28 %) dose groups, there were no obvious
trends suggesting a possible dose relationship. There was no
evidence of accumulation of any specific event within the
individual dose cohorts as the number of events in the 1500-
mg dose group (n= 9, 15 %) was similar to the number of
events in each of the 35-mg (n= 6, 10 %), 100-mg (n= 6,
10 %), and 250-mg (n= 5, 8 %) dose groups.
Clinical laboratory evaluations, including hematology, bio-
chemistry, coagulation, and urinalysis, did not reveal any
dose- or treatment-related changes over time after infusion
of EMD 525797 or placebo. Similarly, there were no clinically
relevant findings based on vital signs, 12-lead ECG, telemetry
and spirometry data, or physical or ophthalmologic examina-
tions to indicate a signal that could be explained by exposure
to study drug. Finally, anti-EMD 525797 antibodies were
detected in 7 of 37 (19 %) of subjects. However, the presence
of such antibodies was not associated with clinical signs or
symptoms.
The healthy volunteers rated the safety and tolerability
of the received treatment exclusively as good and very
good overall. Except for a moderate assessment for the
subject of the 500-mg dose group with increased CRP
values, the investigator’s assessment of the safety and
Table 3 (continued)
EMD 525797 Placebo (Pooled) N= 18
35 mg 100 mg 250 mg 500 mg 1000 mg 1500 mg Overall
N= 6 N= 6 N= 6 N= 6 N= 6 N= 7 N= 37
n (%) E n (%) E n (%) E n (%) E n (%) E n (%) E n (%) E n (%) E
Respiratory, thoracic, and mediastinal disorders
Pharyngolaryngeal pain - - - - - - 1 (17) 1 1 (17) 1 - - 2 (5) 2 1 (6) 1
Skin and subcutaneous tissue disorders
Hyperhidrosis - - - - - - 1 (17) 1 1 (17) 1 - - 2 (5) 2 - -
Rash papular - - - - - - - - - - 1 (14) 1 1 (3) 1 - -
Skin irritation - - - - - - - - - - - - - - 1 (6) 1
Vascular disorders
Hematoma - - - - - - - - - - - - - - 2 (11) 2
Hot flush - - - - - - - - - - - - - - 1 (6) 1
MedDRA medical dictionary for regulatory activities; TEAE treatment-emergent adverse event; TNFα tumor necrosis factor alpha
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tolerability of the administered treatment was also very
good to good. The local tolerability was considered to be
good to very good as well.
Pharmacokinetics
Maximum serum concentrations of EMD 525797 were
reached 1 to 2 h after start of administration (range 1−8 h over
the dose groups) with maximum serum concentration (Cmax)
values increasing nearly in proportion to dose (Figs. 1 and 2a).
Exposure expressed as area under the serum concentration-
time curve (AUC) increased more than proportionally across
the 35-mg to 1500-mg dose range (Fig. 2b). EMD525797was
eliminated from serum with a half-life of 19.3 h in the 35-mg
dose group and 246.1 h in the 1500-mg dose group (Table 4).
Accordingly, total clearance (CL) decreased from 0.209 L/h at
the 35-mg dose to 0.014 L/h at 1500 mg. This dose-
dependency was more pronounced in the lower-dose groups,
but at doses above 250 mg CL started to level off, indicating a
first-order and saturable elimination pathway (Fig. 3). The
volume of distribution (Vz) was small and did not markedly
change with dose. Mean Vz values ranged from 4.1 to 5.9 L,
indicating a low distribution of EMD 525797 into the extra-
vascular space (Table 4). The presence of anti-EMD 525797
antibodies, as detected in 19 % of subjects, did not influence
the PK of EMD 525797.
Pharmacodynamics and safety biomarkers
Assessments indicated that EMD 525797 did not induce
clinically relevant changes in endogenous thrombin poten-
tial, D-dimer, platelet activation, tumor necrosis factor
alpha (TNFα), interleukin 8 (IL-8), or 50 % hemolytic
complement (CH50) in this population of healthy subjects.
No apparent relationship between EMD 525797 serum
concentrations and these various pharmacodynamic pa-
rameters and safety biomarkers could be detected. It was
not possible to draw statistically affirmed conclusions
concerning the counts of circulating endothelial cells and
circulating endothelial progenitor cells per volume of
blood due to the high standard deviations and low sample
size.
Discussion
The results of this first-in-human, Phase 1, single-center,
randomized, double-blind, placebo-controlled study
showed that EMD 525797 at single ascending intravenous
doses ranging from 35 to 1500 mg did not raise any major
safety issues and was well tolerated in healthy male
subjects.
No dose dependency was confirmed in the distribution of
AEs and there was no evidence of accumulation of any spe-
cific event within the individual dose cohorts. Furthermore,
Fig. 1 Serum concentration-time
courses of EMD 525797 for all
investigated dose groups. Values
are presented as mean ± standard




Fig. 2 Dose-adjusted Cmax (a) and AUC (b) of EMD 525797 for all dose
groups. Values are presented as mean ± standard deviation. AUC, area
under the concentration-time curve; Cmax, maximum serum concentration
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there were no clinically relevant dose-related changes in any
of the safety parameters assessed. Seventeen subjects experi-
enced AEs that were considered related to EMD 525797
treatment. There were no serious AEs and no deaths. The
majority of AEs occurred within 48 h of dosing and was of a
mild or moderate intensity in all subjects, except for an in-
crease in CRP level assessed as severe in one subject treated
with 500 mg EMD 525797. All AEs were resolved without
exception at the end of the study. All classes of AE were
reported at a similar level to placebo, except for headaches
(nervous system disorder class), an AE that occurred at a
slightly higher frequency in the EMD525797 group compared
to the placebo group (7 of 37 vs 2 of 18 subjects). However, no
dose relationship observed. Headache is frequently seen in
early drug development studies and a pattern as observed in
this study is common.
Single-dose administration of EMD 525797 showed that
the PKs of this compound were dose-dependent, particularly
at lower doses. This nonlinear PK behavior was driven by
first-order and saturable elimination, which was mostly evi-
dent in the range of 35 to 250 mg. In this dose range, antibody
half-life was not constant but increased markedly with dose.
Thus, at low concentrations the level of receptor binding
predominantly determines antibody clearance, whereas at
doses above 250 mg where receptors can be assumed to be
saturated, catabolism is the primary mechanism associated
with antibody clearance. Total clearance started to level off
at doses above 250 mg, with a further slight trend to decrease
with dose. This was also reflected in the dose-dependency of
the area under the curve extrapolated to infinity, for which
levels increased more than proportionally between 35 and
1500 mg.
Although anti-EMD 525797 antibodies were detected in 7
of 37 (19 %) subjects, no impact on either PK or safety was
Table 4 EMD 525797 PK data
AUC area under the concentra-
tion-time curve; CL clearance;
Cmax maximum serum concen-
tration; PK pharmacokinetic; SD
standard deviation; t1/2, half-life;
Tmax time to maximum serum
concentration; Vz volume of
distribution
EMD 525797
35 mg 100 mg 250 mg 500 mg 1000 mg 1500 mg
N= 6 N= 6 N= 6 N= 6 N= 6 N= 6
Cmax, μg/mL
Mean 5.9 21.9 65.7 141 292 449
(SD) (0.76) (1.75) (7.48) (15.2) (42.0) (58.7)
Range 4.9–6.5 19.3–24.5 54.8–75.1 122–158 229–358 368–521
Tmax, h
Median 1.3 2.0 1.5 1.8 3.5 2.0
Range 1.0–4.0 1.5–3.0 1.0–2.0 1.0–4.0 1.5–8.0 1.0–6.0
AUC0-∞, μg/mL•h
Mean 169 1155 7350 21834 55811 112023
(SD) (20.2) (212.6) (1158) (4936) (9042) (20183)
Range 144–201 932–1513 6538–9421 17438–28809 43219–64439 81964–141859
t1/2, h
Mean 19.3 32.5 92.6 128.7 206.3 246.1
(SD) (3.5) (6.8) (24.4) (35.1) (24.8) (79.1)
Range 13.3–23.2 20.9–40.3 61.2–129.3 95.7–174.4 178.0–248.0 156.7–356.2
CL, L/h
Mean 0.209 0.089 0.035 0.024 0.018 0.014
(SD) (0.024) (0.015) (0.005) (0.005) (0.003) (0.003)
Range 0.18–0.24 0.07–0.11 0.03–0.04 0.02–0.03 0.02–0.02 0.01–0.02
Vz, L
Mean 5.9 4.1 4.5 4.3 5.4 4.7
(SD) (1.5) (0.6) (0.9) (0.9) (0.9) (0.9)
Range 4.2–8.1 3.1–4.8 3.4–5.8 3.2–5.8 4.4–6.5 3.5–5.7
Fig. 3 Clearance of EMD 525797 by dose group
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observed. Moreover, EMD 525797 did not produce any clin-
ically relevant changes in various pharmacodynamic and safe-
ty measures, including ETP, D-dimer, platelet activation, and
several immunologic parameters. These findings suggest there
was no apparent relationship between EMD 525797 serum
concentrations and the assessed pharmacodynamics and safe-
ty parameters.
In conclusion, ascending single doses of EMD 525797
(ranging from 35 to 1500 mg) were shown to be safe and well
tolerated in this first-in-human study of healthy subjects, with
most reported AEs of a similar incidence for EMD 525797
and placebo. No safety concerns were identified and the PK
findings suggest that EMD 525797 is eliminated in a manner
consistent with other antibodies targeting membrane-
associated receptors. This study supported further investiga-
tion of EMD 525797 in randomized trials and provided a basis
for dose selection in currently ongoing trials of EMD 525797
in metastatic castrate-resistant prostate cancer and colorectal
cancer patients.
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